---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-002335"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2022-04-05T23:59:59+00:00"
generated_at: "2026-06-26T09:19:19.249090+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech appoints Dr. Matthias Löhr to Board to fill vacancy from Yuen's death

## Summary
- Dr. Löhr appointed to Board on March 31, 2022; vacancy created by death of Thomas C.K. Yuen.
- Compensation: $12,500 cash per quarter, annual grant of 334 restricted shares and a 5-year option for 334 shares (fully vested).
- Dr. Löhr is Professor of Gastroenterology & Hepatology at Karolinska Institute; led prior Phase 1/2 and Phase 2 trials of the company's pancreatic cancer treatment.
- He will serve on the Compensation and Nominating Committees; independence under Nasdaq rules confirmed.
- No family relationships or related party transactions with the company disclosed.

## SEC filing metadata
- accession: 0001683168-22-002335
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2022-04-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822002335/0001683168-22-002335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822002335/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-002335
- JSON: https://secwatch.observer/filing/0001683168-22-002335.json
- Plain text: https://secwatch.observer/filing/0001683168-22-002335.txt

## Key facts
- Executive change
  Thomas C.K. Yuen departed as Director at PharmaCyte Biotech, Inc..
  - Action: deceased
  - Role: Director
  source text: vacancy created by the recent death of Thomas C.K. Yuen
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822002335/0001683168-22-002335-index.htm
- Executive change
  Matthias Löhr was appointed as Director at PharmaCyte Biotech, Inc..
  - Action: appointed
  - Role: Director
  source text: On March 31, 2022, the Board of Directors ("Board") of PharmaCyte Biotech, Inc., a Nevada corporation ("Company"), appointed Matthias Löhr, MD ("Dr. Löhr") to the Board to fill a vacancy
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822002335/0001683168-22-002335-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.